We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals

61 hedge funds and large institutions have $68.3M invested in Milestone Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 18 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 4

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

198% more capital invested

Capital invested by funds: $22.9M → $68.3M (+$45.4M)

42% more funds holding

Funds holding: 4361 (+18)

18.06% more ownership

Funds ownership: 22.1%40.17% (+18%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

34% less call options, than puts

Call options by funds: $423K | Put options by funds: $641K

Holders
61
Holders Change
+18
Holders Change %
+41.86%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
26
Increased
18
Reduced
4
Closed
7
Calls
$423K
Puts
$641K
Net Calls
-$218K
Net Calls Change
-$880K
Name Holding Trade Value Shares
Change
Change in
Stake
XT
26
XTX Topco
Cayman Islands
$375K +$46.3K +26,338 +16%
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
$287K +$190K +107,800 +303%
HF
28
HRT Financial
New York
$277K +$244K +138,812 New
VFA
29
Valeo Financial Advisors
Indiana
$261K
LPL Financial
30
LPL Financial
California
$191K +$148K +84,250 +762%
GCP
31
GSA Capital Partners
United Kingdom
$157K +$138K +78,747 New
CCAM
32
Cascades Capital Asset Management
North Carolina
$155K +$17.9K +10,200 +15%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$148K +$98.6K +56,064 +312%
Simplex Trading
34
Simplex Trading
Illinois
$133K +$118K +66,920 New
Northern Trust
35
Northern Trust
Illinois
$78.5K -$24.2K -13,743 -26%
Focus Partners Wealth
36
Focus Partners Wealth
Massachusetts
$72K
FDCDDQ
37
Federation des caisses Desjardins du Quebec
Quebec, Canada
$59.6K +$29.5K +16,781 +129%
Raymond James Financial
38
Raymond James Financial
Florida
$53.2K -$29.3K -16,635 -38%
SIAG
39
Safeguard Investment Advisory Group
California
$50.1K
Mariner
40
Mariner
Kansas
$50K +$24.6K +14,000 +127%
Creative Planning
41
Creative Planning
Kansas
$46.8K
State Street
42
State Street
Massachusetts
$44.4K +$6.99K +3,974 +22%
SC
43
Stephenson & Company
California
$40K +$35.2K +20,000 New
National Bank of Canada
44
National Bank of Canada
Quebec, Canada
$37.4K
BRG
45
Bay Rivers Group
Virginia
$33.4K +$4.17K +2,370 +17%
Bank of America
46
Bank of America
North Carolina
$32.1K +$28.2K +16,044 +200,550%
BWG
47
Beta Wealth Group
California
$28.3K
Cambridge Investment Research Advisors
48
Cambridge Investment Research Advisors
Iowa
$25K +$22.3K +12,698 New
SC
49
Sapient Capital
Indiana
$24.8K +$21.5K +12,200 New
Jones Financial Companies
50
Jones Financial Companies
Missouri
$22K

MIST Hedge Fund Activity: Q3 2025 in Review

61 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2025, worth a combined $68.3M — up 198% from $22.9M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new MIST positions and 7 closed out — a net gain of 19 holders — while 18 added to existing stakes and 4 trimmed.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $12.3M. The largest seller was Alta Fundamental Advisers, exiting entirely with an estimated $2.71M sold.

  • 61 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2025, up from 43 in Q2 2025.
  • Funds reported $68.3M of Milestone Pharmaceuticals stock for Q3 2025, up 198% quarter-over-quarter.
  • 26 funds opened new Milestone Pharmaceuticals positions in Q3 2025 and 7 closed out, a net change of +19 holders.
  • The largest Milestone Pharmaceuticals buyer in Q3 2025 was Adage Capital Partners, an estimated $12.3M added.
  • The largest Milestone Pharmaceuticals seller in Q3 2025 was Alta Fundamental Advisers, an estimated $2.71M sold.

Based on aggregated 13F filings for Q3 2025.